Medical promise at a reasonable price

A whistle-stop tour of new faces, farewells, winners and losers

THE COMPANIES BOOSTING RETURNS TO SHAREHOLDERS

FTSE 250 company has a leading position in its market niche

Andrew van Sickle: Shall we start with an overview of your fund? Daniel Avigad: The TM Lansdowne European Special Situations Fund is a long-only, mid- to large cap-focused Europe ex-UK fund. We concen

WHO IS WINNING BETWEEN NOVO-NORDISK AND ELI LILLY?

ONE OF MODERN HEALTHCARE’S BIGGEST AND COSTLIEST ...